APTO - שווי פעילות לרווח לפני ריבית, מסים ופחת Aptose Biosciences Inc.

The share price for Aptose Biosciences Inc. (APTO) visualized below on the GURU.Markets platform, with an EV/EBITDA of , is based on the development of innovative small molecules for kinase inhibition in tumors. However, a severe cash burn puts tuspetinib trials at risk and threatens shareholders with delisting and capital loss. The business foundation remains the ownership of inhibitor patents, which promises future licensing payments.

Investors evaluate capital management efficiency by comparing the total enterprise value of a business with its operating profit before depreciation and interest. This multiple determines the real value of assets, stripped of tax effects and debt load. For Aptose Biosciences Inc. (APTO), raw material supply chain disruption risks directly impact operating cash flow, which is reflected in the fluctuations of the EV/EBITDA ratio.